PDCD1 and gastric cancer: In second-line therapy for advanced GC, apatinib plus toripalimab treatment (anti-PD-1 therapy) demonstrated tolerable toxicity but did not improve clinical outcomes in comparison with the physician’s chosen chemotherapeutic treatment plan.